Vaccinex 8/31/2026 Earnings Report

Vaccinex EPS Results

• Actual EPS: N/A
• Consensus EPS: -$73.04
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Vaccinex Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $0.63 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Vaccinex Announcement Details

• Date: 8/31/2026
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Vaccinex (NASDAQ:VCNX) is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting oncology and neurodegenerative diseases. Headquartered in Rochester, New York, Vaccinex harnesses its proprietary human antibody platform to modulate the semaphorin 4D (SEMA4D) pathway, a mechanism implicated in tumor immune evasion and neuroinflammatory processes. Its lead asset, pepinemab (VX15/2503), is an investigational monoclonal antibody designed to bind and block SEMA4D, thereby promoting immune cell infiltration in tumors and supporting neural repair in degenerative disorders.

In oncology, Vaccinex has advanced pepinemab through Phase 2 trials in solid tumors and hematologic malignancies, exploring its potential to enhance the efficacy of established checkpoint inhibitors. Concurrently, the company is conducting a pivotal Phase 2/3 study in early Huntington’s disease, evaluating pepinemab’s ability to slow cognitive and functional decline. Vaccinex’s pipeline also includes preclinical candidates targeting additional indications driven by SEMA4D biology, supported by collaborations with academic institutions and industry partners.

Founded in the early 2000s, Vaccinex operates primarily in the United States, where it manages its clinical development, regulatory affairs and manufacturing activities. Under the leadership of President and CEO David Hallal, the company remains focused on advancing its strategic pipeline toward key regulatory milestones and potential commercialization, leveraging partnerships to broaden its research and development capabilities.